4th Fc-Mediated Function Summit (REGISTRATION ALMOST CLOSING)

Welcome to the 4th Fc-Mediated Function Summit - Your Gateway to Advancing Therapeutic Frontiers!

FINAL 5 PASSES REMAINING - Register now at https://ter.li/g3wvmz

Supercharge FcRn, FcγR, and IgG: Understand Targets and Biology to Advance Molecular Development, Clinical Utility, and Novel Therapeutic Applications

As 2023 delivered a second FcRn inhibitor approval, clinically validating the transformative potential of neonatal Fc receptors across autoimmunity and IO, the therapeutic age of blocking FcRn-IgG interactions and optimized Fc-modulation through Fc-engineering strategies in the latest generation of antibody design is underway.

VCs, immunology, and inflammation experts at pharma and biotech are shifting from IO to autoimmunity and the ArgenX-Genmab partnership has catalyzed new work in Fc-engineering; the 4th Fc-Mediated Function Summit is your opportunity to evaluate the transformative potential of FcRn over corticosteroids, immunosuppressants, and B-cell depletion. This is the industry sandpit for intense conversations and networking to advance the next IgG, antibody and FcRn-agonist drugs.

See the full agenda here - https://ter.li/8qkcu9 to discover the insights being shared.

Key Highlights:

Targeting FcRn and FcyR Biology
Unlock the secrets of molecular engineering and real-world clinical outcomes by focusing on the critical targets - FcRn and FcγR. Gain insights into the intricacies of their biological pathways, and understand how molecular modifications can translate into tangible clinical benefits.

Unrivaled Content
As the only conference dedicated exclusively to FcRn, this meeting will comprehensively cover the landscape. Attendees can expect to be immersed in cutting-edge research, the latest advancements, and a holistic understanding of the subject matter. This focus ensures that participants are at the forefront of knowledge and equipped with insights that are not diluted by unrelated topics, setting this summit apart as a beacon of specialized expertise.

Exceptional Networking
Forge meaningful connections with a diverse cohort of professionals spanning immunology, antibody engineering, pharmacology, toxicology, and immuno-oncology. The summit provides a unique opportunity to engage with 80+ peers, facilitating cross-disciplinary partnerships and knowledge exchange.

5 PASSES REMAINING - Register Now! - https://ter.li/g3wvmz

URLs:
Website: https://go.evvnt.com/2159294-0?pid=10018
Tickets: https://go.evvnt.com/2159294-2?pid=10018
Brochure: https://go.evvnt.com/2159294-3?pid=10018

Prices:
Conference + 1 Workshop - Drug Developer Pricing: USD 3598.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + 1 Workshop - Academic Pricing: USD 3098.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + 1 Workshop - Solution Provider Pricing: USD 4398.00,
Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Alicia Chenoweth - Research Associate - King's College London, Anil Thotakura - Head of Immuno-Oncology - Orion Pharma, Ann White - Director, Biomarker Lead - UCB, Bart-Jan de Kreuk - Senior Scientist, Antibody Format Discovery - Genmab, Basil Golding - Director, Division of Plasma Protein Therapeutics - Centre for Biologics Evaluation and Research, Björn Frendéus - Chief Scientific Officer - BioInvent, Daniella Cipoletta - Director, Immunology - Seismic Therapeutic, David Humphreys - Executive Director and Head of Antibody and Novel Therapeutics - UCB, Erik Procko - Director, Discovery - Cyrus Biotechnology Inc., Jamie Mitchell - Scientist - Seagen, Joel Cohen-Solal - Principal Scientist, Head of Fc Biology Team - Abbvie, Julian Chandler - Associate Director - Alexion Pharmaceuticals, Lindsay Avery - Global DMPK Innovation Head - Sanofi, Marjolein van Egmond - Professor and Principle Investigator, Oncology and Inflammation - Amsterdam UMC, Nimish Gera - Vice President, Biologics - Mythic Therapeutics, Rakesh Dixit - President and Chief Scientific Officer - Regio Biosciences, Ryan Fiehler - Associate Director, Discovery - F-Star Therapeutics